Niraparib is an investigational product that is currently in Phase 3 clinical trials for ovarian cancer and BRCA+ breast cancer. Niraparib has not been approved by the FDA or any other regulatory authorities. For more information on participating in a clinical trial of niraparib, please contact email@example.com.
A Study of Niraparib Maintenance Treatment in Patients With HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy (PRIMA)
A Maintenance Study with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer (NOVA)
A Phase III Trial of Niraparib Versus Physician's Choice in Her2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients (BRAVO)
A Study of Niraparib in Patients With Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens (QUADRA)